A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 17 Aug 2012 Actual initiation date (1 Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Apr 2012 New trial record